Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, researchers are actively exploring and approving new Alzheimer’s treatment options. Two FDA-approved disease-modifying treatments—Leqembi (lecanemab) and Kisunla (donanemab)—have demonstrated the ability to slow cognitive decline in early-stage Alzheimer’s disease. These represent a fundamental shift from decades of treatments that only managed symptoms without addressing the underlying disease process.
For the first time, patients diagnosed with mild cognitive impairment or early-stage Alzheimer’s have access to medications that can meaningfully slow disease progression rather than simply delay memory loss. The research landscape has expanded dramatically in 2026, with 138 drugs currently in 182 clinical trials across the Alzheimer’s development pipeline. Beyond the currently approved options, researchers are investigating entirely new approaches—from repurposed medications like erectile dysfunction drugs to emerging targets like tau protein and brain inflammation. This article explores what these new treatments are, how well they work in real-world settings, what trials are underway, and what limitations and challenges patients should understand before starting treatment.
Table of Contents
- What Are the New FDA-Approved Alzheimer’s Treatments?
- How Much Do These Treatments Actually Help?
- What’s in Development—The Current Pipeline
- The Role of Non-Pharmacological Treatments
- Why Are Some Promising Trials Failing?
- Regulatory Decisions Shaping 2026
- The Emerging Frontier of Personalized Treatment
- Conclusion
What Are the New FDA-Approved Alzheimer’s Treatments?
Leqembi and Kisunla represent the first disease-modifying treatments for Alzheimer’s disease, targeting amyloid-beta protein—a hallmark brain change in Alzheimer’s disease. Both medications are monoclonal antibodies designed to remove amyloid buildup from the brain. While they don’t stop Alzheimer’s entirely, they slow the rate of cognitive decline. For someone in early stages, this might mean maintaining independence and cognitive function for additional months or years—a meaningful difference for patients and families planning for the future.
A major recent development is the FDA approval of an at-home injectable form of Leqembi, which allows patients to self-administer the medication instead of traveling to clinics for intravenous infusions. This addresses a significant access barrier and improves quality of life during treatment. The FDA is expected to decide by May 2026 whether to approve starter doses for home use, which would make initiation even more convenient. However, it’s important to note that both medications require amyloid testing (typically via PET scan or blood tests) before treatment begins, and regular monitoring during treatment is necessary.
How Much Do These Treatments Actually Help?
Real-world efficacy data from Leqembi demonstrates a 1.01-point reduction in the clinical Dementia Rating–Sum of Boxes (CDR-SB) score over three years of treatment compared to expected decline in untreated patients. This means that while decline continues, it slows noticeably. To understand what this means practically: a typical untreated patient with early Alzheimer’s might lose 3-4 points on the CDR-SB over three years, while a treated patient might lose 2-3 points. This slowing effect preserves quality of life and independence during a critical window.
The limitation here is significant: these treatments work best in the earliest stages of disease, when amyloid pathology is prominent but cognitive symptoms are still mild. They do not reverse damage already done, and they work only in patients who test positive for amyloid in the brain. Additionally, both Leqembi and Kisunla carry a risk of amyloid-related imaging abnormalities (ARIA), which can include microhemorrhages or brain swelling. Most cases are asymptomatic and monitored via MRI, but this side effect requirement means patients need regular neuroimaging, adding time, cost, and ongoing medical appointments to treatment.
What’s in Development—The Current Pipeline
With 138 drugs in 182 clinical trials, the pipeline includes several promising approaches beyond amyloid-targeting. Trontinemab, a next-generation amyloid-targeting drug, has entered Phase III clinical trials and represents optimization of the current successful strategy. More intriguingly, AriBio’s AR1001—a repurposed erectile dysfunction medication—is in Phase 3 trials with results expected in the latter half of 2026. This drug targets a different mechanism and involves more than 1,500 participants, offering potential for patients who cannot tolerate or do not respond to amyloid-targeting drugs.
Other emerging targets extend far beyond amyloid: researchers are investigating tau protein, neuroinflammation, brain lipid handling, and metabolic dysfunction. This diversification is crucial because amyloid-beta is not the only problem in Alzheimer’s brains—tau tangles, inflammation, and energy metabolism dysfunction all contribute to neuronal death. By developing drugs targeting these alternative mechanisms, researchers may eventually offer combination therapies tailored to individual disease subtypes. Lithium, an old psychiatric medication, is being researched as a potential prevention or reversal agent, though evidence remains preliminary.
The Role of Non-Pharmacological Treatments
Beyond medication, researchers are investigating non-drug approaches including brain stimulation techniques and focused ultrasound, which can theoretically open the blood-brain barrier and enhance delivery of other treatments. These approaches address a fundamental limitation of many Alzheimer’s drugs: difficulty crossing the blood-brain barrier to reach affected neurons. Non-pharmacological options may eventually work alongside medications rather than as replacements.
Practical decision-making around these options involves weighing convenience, side effect profiles, and evidence strength. Medications like Leqembi offer substantial evidence but require regular clinic visits or home infusions, amyloid testing, MRI monitoring, and commitment to ongoing treatment. Emerging approaches may eventually offer better tolerability or effectiveness but currently lack the clinical evidence backing of approved drugs. This trade-off means that patients with early-stage Alzheimer’s today benefit from starting approved medications while staying informed about emerging options in trials.
Why Are Some Promising Trials Failing?
Not all research leads to successful treatments. Novo Nordisk’s semaglutide—a diabetes and weight-loss medication showing promise in preliminary research—failed both Phase 3 trials (EVOKE and EVOKE+) at 104 weeks with no difference from placebo. The program has been terminated. Similarly, Johnson & Johnson’s posdinemab, an anti-tau antibody that showed theoretical promise, failed its pivotal trial with no efficacy at the two-year mark.
These failures highlight a critical limitation: early laboratory findings and theoretical targets don’t always translate to human benefit. These setbacks actually provide valuable information. Failed trials tell researchers which pathways won’t work, preventing wasted resources and allowing focus on more promising directions. They also remind patients and families that Alzheimer’s research faces genuine scientific uncertainty—not every promising approach succeeds. The failures underscore why starting with approved treatments while they’re available remains prudent, rather than waiting indefinitely for hypothetical improved options.
Regulatory Decisions Shaping 2026
Multiple FDA decisions are expected in 2026 that will affect treatment options. The FDA decision on Axsome Therapeutics’ AXS-05 for treating Alzheimer’s disease agitation is expected by April 30, 2026. While agitation is a behavioral symptom rather than a disease-modifying treatment, managing it effectively reduces suffering and improves quality of life for patients and caregivers.
Additionally, the expected May 2026 decision on home starter doses of Leqembi would substantially improve access by eliminating the need to initiate treatment in medical clinics. These decisions reflect a broader trend toward patient convenience and treatment accessibility. The shift from clinic-based IV infusions to at-home injections exemplifies how regulatory approval can fundamentally change what’s feasible for patients managing chronic disease. For someone considering treatment, these 2026 decisions may determine whether disease-modifying therapy is practically achievable given their life circumstances.
The Emerging Frontier of Personalized Treatment
The future of Alzheimer’s treatment likely involves moving beyond one-size-fits-all approaches. Different patients have different combinations of amyloid, tau, inflammation, and metabolic problems driving their disease. As the pipeline expands with multiple drug targets and mechanisms, treatment will increasingly involve testing individual patients to determine which drug combinations make sense.
This represents a shift toward precision medicine in neurodegenerative disease. The research community is also increasingly focused on earlier intervention—potentially treating cognitively normal people who have biomarker evidence of Alzheimer’s pathology. Prevention trials are underway, based on the logic that stopping disease before symptoms appear would be more effective than treating established cognitive decline. This approach could transform Alzheimer’s from a disease managed after symptoms appear into one prevented entirely in some patients.
Conclusion
Researchers have moved Alzheimer’s disease treatment from symptom management into disease modification. Leqembi and Kisunla represent genuine advances that slow cognitive decline in early-stage disease, with the added benefit of increasingly convenient at-home administration. A robust pipeline of 138 drugs in clinical trials suggests continued innovation and expansion of treatment options beyond current amyloid-targeting approaches. Regulatory decisions in 2026 will likely improve accessibility and add new options for managing behavioral symptoms.
However, anyone considering Alzheimer’s treatment should understand both the benefits and the limitations. Current treatments work best in early stages, require biomarker confirmation, involve ongoing medical monitoring, and carry side effects including risk of brain microhemorrhages or swelling. Some promising approaches—including repurposed diabetes medications and alternative drug targets—remain in trials with uncertain timelines to approval. The most practical approach for someone with early Alzheimer’s today is to discuss approved options with a neurologist while staying informed about emerging developments in this rapidly advancing field.
